Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferonpositive and interferon-negative patients with primary Sjögren's syndrome

Annals of the Rheumatic Diseases

Volumn 76, Issue 4, 2017, Pages 721-730

  Maria, Naomi I ^a   Steenwijk, Eline C ^a   IJpma, Arne S ^a   Van Helden Meeuwsen, Cornelia G ^a   Vogelsang, Petra ^b,c   Beumer, Wouter ^a   Brkic, Zana ^a   Van Daele, Paul L A ^a   Van Hagen, P Martin ^a   Van Der Spek, Peter J ^a   Drexhage, Hemmo A ^a   Versnel, Marjan A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 7; DDX58 PROTEIN, HUMAN; IFIH1 PROTEIN, HUMAN; INTERFERON REGULATORY FACTOR 7; IRF7 PROTEIN, HUMAN; MESSENGER RNA; MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN; RSAD2 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; UPREGULATION; AGED; BLOOD; CELL CULTURE; CHEMISTRY; DENDRITIC CELL; DNA MICROARRAY; GENETICS; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; SALIVARY GLAND;

ADULT; AGED; CELLS, CULTURED; DEAD BOX PROTEIN 58; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERON TYPE I; INTERFERON-INDUCED HELICASE, IFIH1; MALE; MIDDLE AGED; MONOCYTES; MYELOID DIFFERENTIATION FACTOR 88; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEINS; RNA, MESSENGER; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TOLL-LIKE RECEPTOR 7; UP-REGULATION;

EID: 84991665836     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209589     Document Type: Article

References (52)

1. Kirou KA, Lee C, George S, et al. Activation of the interferon-Alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503
2. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogrens syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72:728-35
3. Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogrens syndrome. Ann Rheum Dis 2014;73:1052-9
4. Ronnblom L, Pascual V. The innate immune system in SLE: Type I interferons and dendritic cells. Lupus 2008;17:394-9
5. Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: primary Sjogrens syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2006;2:262-9
6. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004;16:801-7
7. Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-36
8. Guiducci C, Ott G, Chan JH, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006;203:1999-2008
9. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010;234:142-62
10. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594-606
11. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7
12. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjogrens syndrome: A putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-33
13. Yasuda K, Richez C, Maciaszek JW, et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 2007;178:6876-85
14. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-50
15. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14
16. Rice GI, del Toro Duany Y, Jenkinson EM, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014;46:503-9
17. Funabiki M, Kato H, Miyachi Y, et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 2014;40:199-212
18. Ablasser A, Poeck H, Anz D, et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol 2009;182:6824-33
19. Szabo A, Magyarics Z, Pazmandi K, et al. TLR ligands upregulate RIG-I expression in human plasmacytoid dendritic cells in a type I IFN-independent manner. Immunol Cell Biol 2014;92:671-8
20. Szabo A, Rajnavolgyi E. Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: TRIGgering antiviral innate immune responses. Am J Clin Exp Immunol 2013;2:195-207
21. Garcia MA, Gil J, Ventoso I, et al. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006;70:1032-60
22. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogrens syndrome. Proc Natl Acad Sci USA 2006;103:2770-5
23. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogrens syndrome: A possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95
24. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogrens syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8
25. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogrens syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogrens syndrome. Ann Rheum Dis 2010;69:1103-9
26. Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-Type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001;194:1823-34
27. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002;63:1133-48
28. Zhang X, Lepelley A, Azria E, et al. Neonatal plasmacytoid dendritic cells (pDCs) display subset variation but can elicit potent anti-viral innate responses. PLoS ONE 2013;8:e52003
29. Saitoh T, Satoh T, Yamamoto N, et al. Antiviral protein Viperin promotes Toll-like receptor 7-And Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Immunity 2011;34:352-63
30. Seo JY, Yaneva R, Cresswell P. Viperin: A multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe 2011;10:534-9
31. Platanias LC. Mechanisms of type-I-And type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86
32. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90
33. Birmachu W, Gleason RM, Bulbulian BJ, et al. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. BMC Immunol 2007;8:26
34. Miyashita M, Oshiumi H, Matsumoto M, et al. DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol Cell Biol 2011;31:3802-19
35. Maria NI, van Helden-Meeuwsen CG, Brkic Z, et al. Association of increased Treg cell levels with elevated Indoleamine-2, 3-dioxygenase activity and an imbalanced Kynurenine pathway in Interferon-positive primary Sjogrens syndrome. Arthritis Rheumatol 2016;68:1688-99
36. Boneparth A, Huang W, Bethunaickan R, et al. TLR7 influences germinal center selection in murine SLE. PLoS ONE 2015;10:e0119925
37. Jackson SW, Scharping NE, Kolhatkar NS, et al. Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation J Immunol 2014;192:4525-32
38. Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-28
39. Deane JA, Pisitkun P, Barrett RS, et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007;27:801-10
40. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35
41. Desnues B, Macedo AB, Roussel-Queval A, et al. TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci USA 2014;111:1497-502
42. Maria NI, Vogelsang P, Versnel MA. The clinical relevance of animal models in Sjogrens syndrome: The interferon signature from mouse to man. Arthritis Res Ther 2015;17:172
43. Hovanessian AG. The double stranded RNA-Activated protein kinase induced by interferon: dsRNA-PK. J Interferon Res 1989;9:641-7
44. Gestermann N, Mekinian A, Comets E, et al. STAT4 is a confirmed genetic risk factor for Sjogrens syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun 2010;11:432-8
45. Nguyen CQ, Peck AB. The interferon-signature of Sjogrens syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol 2013;4:142
46. Peck AB, Nguyen CQ. Transcriptome analysis of the interferon-signature defining the autoimmune process of Sjogrens syndrome. Scand J Immunol 2012;76:237-45
47. Ronnblom L, Eloranta ML, Alm GV. Role of natural interferon-Alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 2003;36:463-72
48. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008;223:271-83
49. Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007;37:3582-6
50. Lamphier M, Zheng W, Latz E, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol 2014;85:429-40
51. Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-Alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 2009;265:43-57
52. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009;21:317-37